REGN has been granted a new patent
Mar 12, 2025, 10:33 PM
-20.78%
What does REGN do
Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
REGN filed a patent for "bispecific antigen-binding molecules and uses thereof" on Fri, August 25, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.